The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review)

International Journal of Oncology

Volumn 32, Issue 6, 2008, Pages 1145-1157

  Oei, Angèle L M ^a   Sweep, Fred C G J ^a   Thomas, Chris M G ^a   Boerman, Otto C ^a   Massuger, Leon F A G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CA 125; gp38; HER2; HMFG; Monoclonal antibodies; MUC1; Ovarian cancer; TAG 72; VEGF

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CHIMERIC MONOCLONAL ANTIBODY MOV18; CYCLOPHOSPHAMIDE; EDETATE CALCIUM DISODIUM; FLUOROURACIL; HUMAN MILK FAT GLOBULE 1 MONOCLONAL ANTIBODY; HUMAN MILK FAT GLOBULE 1 MONOCLONAL ANTIBODY Y 90; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ACA 125; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY B.72.3 Y 90; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 LU 177; MONOCLONAL ANTIBODY CC49 Y 90; MONOCLONAL ANTIBODY MDX H210; MONOCLONAL ANTIBODY MOV18 I 131; MONOCLONAL ANTIBODY OC/TR; MONOCLONAL ANTIBODY OC125 I 131; MONOCLONAL ANTIBODY OC125 IN 111; OREGOVOMAB; OREGOVOMAB TC 99M; PACLITAXEL; PERTUZUMAB; PLACEBO; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER IMMUNIZATION; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; HUMORAL IMMUNITY; HYPONATREMIA; IMMUNOGENICITY; MEDLINE; METABOLIC DISORDER; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVARY CANCER; PAIN; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REPEATED DRUG DOSE; REVIEW; RIGOR; SERUM SICKNESS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; WEAKNESS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; OVARY TUMOR;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 48149110374     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_32_6_1145     Document Type: Review

References (118)

1. Brewer MA, Johnson K, Follen M, Gershenson D and Bast R Jr: Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9: 20-30, 2003.
2. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
4. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. Int J Gynaecol Obstet 83 (Suppl. 1): 135-166, 2003.
5. Grillo-Lopez AJ, Hedrick E, Rashford M and Benyunes M: Rituximab: ongoing and future clinical development. Semin Oncol 29: 105-112, 2002.
6. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D and Brittinger G: Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 81: 26-32, 2002.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.
9. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208, 2004.
10. Gura T: Therapeutic antibodies: magic bullets hit the target. Nature 417: 584-586, 2002.
11. Ehrlich P: Collected Studies on Immunology. John Wiley, New York, 1906.
12. Kohler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
13. Linenberger ML, Maloney DG and Bernstein ID: Antibody-directed therapies for hematological malignancies. Trends Mol Med 8: 69-76, 2002.
14. Yokota T, Milenic DE, Whitlow M and Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-3408, 1992.
15. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43: 693-713, 2002.
16. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL and Schlom J: Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 53: 3776-3783, 1993.
17. Iannello A and Ahmad A: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 24: 487-499, 2005.
18. Herlyn D, Ross AH and Koprowski H: Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 232: 100-102, 1986.
19. Jerne NK: Towards a network theory of the immune system. Ann Immunol 125C: 373-389, 1974.
20. De Nardo GL, Bradt BM, Mirick GR and De Nardo SJ: Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 52: 309-316, 2003.
21. Khazaeli MB, Conry RM and Lo Buglio AF: Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15: 42-52, 1994.
22. Van Kroonenburgh MJ and Pauwels EK: Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun 9: 919-930, 1988.
23. Kricka LJ: Human anti-animal antibody interferences in immunological assays. Clin Chem 45: 942-956, 1999.
24. Klee GG: Human anti-mouse antibodies. Arch Pathol Lab Med 124: 921-923, 2000.
25. Azinovic I, De Nardo GL, Lamborn KR, et al: Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55: 1451-1458, 2006.
26. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H and Frodin JE: Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-lA. Cancer Immunol Immunother 42: 81-87, 1996.
27. Miotti S, Negri DR, Valota O, et al: Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 84: 62-68, 1999.
28. Wagner UA, Oehr PF, Reinsberg J, et al: Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. Biotechnol Ther 3: 81-89, 1992.
29. Morrison SL, Johnson MJ, Herzenberg LA and Oi VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81: 6851-6855, 1984.
30. Green LL, Hardy MC, Maynard-Currie CE, et al: Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7: 13-21, 1994.
31. Wagner SD, Williams GT, Larson T, et al: Antibodies generated from human immunoglobulin miniloci in transgenic mice. Nucleic Acids Res 22: 1389-1393, 1994.
32. Dillman RO, Beauregard JC, Halpern SE and Clutter M: Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. J Biol Response Mod 5: 73-84, 1986.
33. Frodin JE, Lefvert AK and Mellstedt H: The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 21: 153-165, 1992.
34. Kimby E: Tolerability and safety of rituximab. (MabThera) Cancer Treat Rev 31: 456-473, 2005.
35. Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12: 184-193, 1994.
36. Agus DB, Gordon MS, Taylor C, et al: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534-2543, 2005.
37. Berek JS, Taylor PT, Gordon A, et al: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22: 3507-3516, 2004.
38. Bolhuis RL, Lamers CH, Goey SH, et al: Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer (Suppl) 7: 78-81, 1992.
39. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA and Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21: 283-290, 2003.
40. Burger RA, Sill M, Monk BJ, Greer B and Sorosky J: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J Clin Oncol 23: 457s (suppl) abs 5009, 2005.
41. Canevari S, Stoter G, Arienti F, et al: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87: 1463-1469, 1995.
42. Cannistra SA, Matulonis UA, Penson R, Wenham R, Armstrong R and Burger RA: bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol 24: 18S (suppl) abs 5006, 2006.
43. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ and Fowler JM: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102: 134-139, 2006.
44. De Gramont GA, Gangji D, Louvet C, Garcia ML, Tardy D and Romet-Lemonne JL: Adoptive immunotherapy of ovarian carcinoma. Gynecol Oncol 86: 102-103, 2002.
45. Ehlen TG, Gordon AN, Fingert HJ, Nicodemus CF, Schultes B and Whiteside TL: Adjuvant treatment with monoclinal antibody, OvaRex MAb-43.13 (OV) targeting CA 125, induces robust immune responses associated with prolonged time to relapse in a randomized controlled study in patients with advanced epithelial ovarian cancer (EOC). J Clin Oncol ASCO, abs 31,2002.
46. Ehlen TG, Hoskins PJ, Miller D, et al: A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15: 1023-1034, 2005.
47. Garcia AA, Oza AM, Hirte H, et al: Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. J Clin Oncol 23: 16s (suppl) abs 5000, 2005.
48. Gordon AN, Schultes BC, Gallion H, et al: CA 125 and tumor-specific T-cell response correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94: 340-351, 2004.
49. Gordon MS, Matei D, Aghajanian C, et al: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24: 4324-4332, 2006.
50. Lamers CH, Gratama JW, Warnaar SO, Stoter G and Bolhuis RL: Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer 60: 450-457, 1995.
51. Lamers CH, Bolhuis RL, Warnaar SO, Stoter G and Gratama JW: Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int J Cancer 73: 211-219, 1997.
52. Method MW, Gordon AN, Finkler N, Cieszynski J and Nicodemus CF: Final analysis of a randornized dosing study of oregovomab in patients with advanced ovarian cancer. J Clin Oncol 23: 16S (suppl) abs 5035, 2005.
53. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G and Burger RA: Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovadan cancer. Gynecol Oncol 102: 140-144, 2006.
54. Schultes BC, Baum RP, Niesen A, Noujaim AA and Madiyalakan R: Anti-idiotype induction therapy: anti-CA 125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 46: 201-212, 1998.
55. Seiden MV, Burris HA, Matulonis U, et al: A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104: 727-731, 2007.
56. Van Zanten-Przybysz I, Molthoff C, Gebbinck JK, et al: Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOvl8 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol 128: 484-492, 2002.
57. Wright JD, Hagemann A, Rader JS, et al: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107: 83-89, 2006.
58. Nicholson S, Bomphray CC, Thomas H, et al: A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 53: 809-816, 2004.
59. Reinartz S, Kohler S, Schlebusch H, et al: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10: 1580-1587, 2004.
60. Wagner U, Schlebusch H, Kohler S, Schmolling J, Grunn U and Krebs D: Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA 125. Hybridoma 16: 33-40, 1997.
61. Wagner U, Kohler S, Reinartz S, et al: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA 125: immune responses and survival in palliative treatment. Clin Cancer Res 7: 1154-1162, 2001.
62. Pfisterer J, Du BA, Sehouli J, et al: The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer, a phase I trial of the AGO-OVAR. Ann Oncol 17: 1568-1577, 2006.
63. Alvarez RD, Partridge EE, Khazaeli MB, et al: Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65: 94-101, 1997.
64. Alvarez RD, Huh WK, Khazaeli MB, et al: A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8: 2806-2811, 2002.
65. Baum RP, Niesen A, Hertel A, et al: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 73: 1121-1125, 1994.
66. Crippa F, Bolis G, Seregni E, et al: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinica1 results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A: 686-690, 1995.
67. Epenetos AA, Hird V, Lambert H, Mason P and Coulter C: Long-term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10: 44-46, 2000.
68. Hird V, Maraveyas A, Snook D, et al: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68: 403-406, 1993.
69. Mahe MA, Fumoleau P, Fabbro M, et al: A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5: S3249-S3253, 1999.
70. Meredith RF, Partridge EE, Alvarez RD, et al: Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 37: 1491-1496, 1996.
71. Meredith RF, Alvarez RD, Partridge EE, et al: Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 16: 305-315, 2001.
72. Mobus VJ, Baum RP, Bolle M, et al: Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 189: 28-36, 2003.
73. Muto MG, Finkler NJ, Kassis AI, et al: Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine- 131-labeled monoclonal antibody OC 125. Gynecol Oncol 45: 265-272, 1992.
74. Nicholson S, Gooden CS, Hird V, et al: Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep 5: 223-226, 1998.
75. Nicholson S, Bell S, McCormack M, Bomphray CC, Ganesan T and Gore M: A randomised phase III trial of adjuvant intraperitoneal radioimmunotherapy in ovarian cancer. J Clin Oncol ASCO, abs 1514, 2000.
76. Rosenblum MG, Verschraegen CF, Murray JL, et al: Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5: 953-961, 1999.
77. Stewart JS, Hird V, Snook D, et al: Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 8: 1941-1950, 1990.
78. Verheijen RH, Massuger LF, Benigno BB, et al: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24: 571-578, 2006.
79. 131I-labeled chimeric monoclonal antibody MOvl8 in patients with ovarian cancer. J Nucl Med 41: 1168-1176, 2000.
80. Madiyalakan R, Sykes TR, Dharampaul S, et al: Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after adrninistration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 14: 199-203, 1995.
81. Noujaim AA, Schultes BC, Baum RP and Madiyalakan R: Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 16: 187-203, 2001.
82. Wagner U: Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma 12: 521-528, 1993.
83. Miotti S, Canevari S, Menard S, et al: Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39: 297-303, 1987.
84. Buijs WC, Tibben JG, Boerman OC, et al: Dosimetric analysis of chimeric monoclonal antibody cMOvl8 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med 25: 1552-1561, 1998.
85. Molthoff CF, Prinssen HM, Kenemans P, van Hof AC, Den HW and Verheijen RH: Escalating protein doses of chimeric mono-clonal antibody MOvl8 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 80: 2712-2720, 1997.
86. Van Zanten-Przybysz I, Molthoff CF, Roos JC, et al: Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOvl8: iv. vs. ip. Int J Cancer 92: 106-114, 2001.
87. Tibben JG, Boerman OC, Massuger LF, Schijf CP, Claessens RA and Corstens FH: Pharmacokinetics, biodistribution and biological effects of intravenously admi-nistered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int J Cancer 66: 477-483, 1996.
88. Van Dijk J, Warnaar SO, van Eendenburg JD, et al: Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 43: 344-349, 1989.
89. Legge F, Ferrandina G, Salutari V and Scambia G: Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol 16 (Suppl 4): iv95-iv101,2005.
90. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC and Bast RC Jr: Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1: 181-190, 1994.
91. Camilleri-Broet S, Hardy-Bessard AC, Le TA, et al: HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 15: 104-112, 2004.
92. Brand FX, Ravanel N, Gauchez AS, et al: Prospect for anti-her2 receptor therapy in breast cancer. Anticancer Res 26: 715-722, 2006.
93. Ocana A, Hortobagyi GN and Esteva FJ: Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer 6: 495-504, 2006.
94. Adams CW, Allison DE, Flagella K, et al: Humanization of a recombinant monoclonal anubody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717-727, 2006.
95. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
96. Valone FH, Kaufman PA, Guyre PM, et al: Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13: 2281-2292, 1995.
97. Valone FH, Kaufman PA, Guyre PM, et al: Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother 4: 471-475, 1995.
98. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL and Bodmer WF: Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28: 17-21, 1981.
99. Epenetos AA, Britton KE, Mather S, et al: Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet 2: 999-1005, 1982.
100. Granowska M, Britton KE, Shepherd JH, et al: A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer. J Clin Oncol 4: 730-736, 1986.
101. Kosmas C, Kalofonos HP and Epenetos AA: Radiolabelled monoclonal antibodies in tumour diagnosis and therapy. Dev Biol Stand 71: 93-102, 1990.
102. Malamitsi J, Skarlos D, Fotiou S, et al: Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. J Nucl Med 29: 1910-1915, 1988.
103. Pectasides D, Pateniotis K, Tzimis L, et al: Immunoscintigraphy with 131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients. Int J Cancer (Suppl) 3: 83-88, 1988.
104. Rosner D, Nabi H, Wild L, Ortman-Nabi J and Hreshchyshyn MM: Diagnosis of breast carcinoma with radiolabeled monoclonal antibodies (MoAbs) to carcinoembryonic antigen (CEA) and human milk fat globulin (HMFG). Cancer Invest 13: 573-582, 1995.
105. Maraveyas A, Snook D, Hird V, et al: Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmuno-conjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 73: 1067-1075, 1994.
106. Courtenay-Luck NS, Epenetos AA, Moore R, et al: Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46: 6489-6493, 1986.
107. Kosmas C, Man S, Epenetos AA and Courtenay-Luck NS: The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy. Br J Cancer (Suppl) 10: 85-88, 1990.
108. Kosmas C, Epenetos AA and Courtenay-Luck NS: Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer 64: 494-500, 1991.
109. Kosmas C, Epenetos AA and Courtenay-Luck NS: Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 73: 3000-3010, 1994.
110. Oei AL, Verheijen RH, Seiden MV, et al: Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 120: 2710-2714, 2007.
111. Rosenblum MG, Kavanagh JJ, Burke TW, et al: Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst 83: 1629-1636, 1991.
112. Krag DN, Ford P, Smith L, et al: Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111-labeled B72.3 monoclonal antibody. Arch Surg 128: 819-823, 1993.
113. Kuroki M, Fernsten PD, Wunderlich D, et al: Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. Cancer Res 50: 4872-4879, 1990.
114. Roselli M, Guadagni F, Buonomo O, et al: Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcino-embryonic antigen. J Clin Oncol 14: 2031-2042, 1996.
115. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
116. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989, 2001.
117. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
118. Burger RA: Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25: 2902-2908, 2007.